Arcutis Biotherapeutics, Inc. vs Johnson & Johnson — Stock Comparison
Arcutis Biotherapeutics, Inc. (ARQT) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson narrowly edges Arcutis Biotherapeutics, Inc. on Q·Score (7.1 vs 6.7 out of 10), primarily on Quality (9.3 vs 3.5). Arcutis Biotherapeutics, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for ARQT (+32.1%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $34.63 is 32% above current price.
⚠ currently unprofitable (-1% margin).
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ARQT vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Arcutis Biotherapeutics, Inc. (ARQT) at 6.7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ARQT or JNJ?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Growth (7.7/10 vs 5.1/10). Arcutis Biotherapeutics, Inc. reports revenue growth (60.1% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ARQT or JNJ more attractively valued?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Valuation (8.1/10 vs 7.3/10). ARQT trades at 22.7× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ARQT vs JNJ?
There are 8 analysts covering ARQT with a consensus price target of $34.63, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ARQT or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 3.5/10). Net profit margin: ARQT at -0.6%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ARQT or JNJ?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Financial Health (7.4/10 vs 6.5/10). Market beta: ARQT at 1.52, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ARQT and JNJ?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalisation of $3.3B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →